PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors
Cellular Oncology · 2024
DOI: 10.1007/s13402-024-00977-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Xianglai Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai, 200032, China. xl.xu@hotmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Biomarkers, Tumor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Zhongshan Clinical Research Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai, 200032, China. xl.xu@hotmail.com.
- Department of Urology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China. xl.xu@hotmail.com.
- Department of Urology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai, 200032, China.
- Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Förderung
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
- Zhongshan Clinical Research Project
- Shanghai Sailing Program
- China Urological Oncology Research Fund
Zitieren
APA
Xu, X., Wang, J., Wang, Y., Zhu, Y., Wang, J., & Guo, J. (2024). PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors. Cellular Oncology. https://doi.org/10.1007/s13402-024-00977-z
Vancouver
Xu X, Wang J, Wang Y, Zhu Y, Wang J, Guo J. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors. Cellular Oncology. 2024. doi:10.1007/s13402-024-00977-z
BibTeX
@article{Xu2024,
author = {Xu, Xianglai and Wang, Jiahao and Wang, Ying and Zhu, Yanjun and Wang, Jiajun and Guo, Jianming},
title = {PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors},
journal = {Cellular Oncology},
year = {2024},
doi = {10.1007/s13402-024-00977-z}
}
EUVIMED